Indeed, in several research studies conducted in BC patients, the presence of ESR1 mutations predicted poor response to AI treatment, yet contrastingly, only Y537S mutations conferred relative resistance to fulvestrant treatment. The gene discussed is ESR1; the disease is breast cancer.